Interest of the Chair Lift Test in the Prognostic Evaluation of Pulmonary Embolism: a Single-center Open Prospective Study

NCT06166329 | Recruiting

• 1 other identifier: 2021/0386/HP
• Study Type: interventional
• Target: 180
• Locations: 1 country
• Sites: 1

Brief Summary

The objective of the study is to evaluate the prognostic performance of the chair lift test in the initial assessment of the severity of non-severe pulmonary embolism in hospitalized patients, in comparison with the current pulmonary embolism risk stratification score using the sPESI score refined by the use of cardiac biomarkers and right ventricular dysfunction

Conditions

Non-severe Pulmonary Embolism; Prognostic Stratification; Pulmonary Embolism; Non-high-risk Pulmonary Embolism; Pulmonary Embolism Acute; Risk Assessment in Pulmonary Embolism; Functional Exercise Testing; Early Prognostic Evaluation

Keywords

Pulmonary Embolism; Prognostic Evaluation; Risk Stratification; sPESI Score; Chair Stand Test; One-Minute Sit-to-Stand Test; Functional Capacity; Right Ventricular Dysfunction; Cardiac Biomarkers; Troponin; NT-proBNP; Early Mortality; Ambulatory Management; Hospitalized Patients

Outcome Measures

Primary Outcomes (1)

• sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the one-minute chair rise test in comparison with the gold standard refined by the use of cardiac biomarkers and right ventricular dysfunction

  1 day

Secondary Outcomes (3)

• Troponin measurement

  1 day

• Presence or absence of post-pulmonary embolism dyspnea

  6 months

• Overall survival

  6 months

Study Arms (1)

chair lift test

EXPERIMENTAL

Other: chair lift test

Interventions

chair lift test OTHER

repetitions of the sit-stand position at a self-timed speed (safe and comfortable) as many times as possible for 1 minute

chair lift test

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosis of pulmonary embolism according to clinical algorithm, confirmed by thoracic angioscan or ventilation perfusion (V/P) scan,
• Non-serious pulmonary embolism, not requiring intensive care (thrombectomy or fibrinolysis not considered).
• sPESI score ≥ 1 \[or = 0 with elevated troponin or presence of markers of VD dysfunction, or = 0 with need for hospitalization due to comorbidities unrelated to PE (social isolation, comprehension disorders, intercurrent infection, chronic renal failure, advanced cancer...)
• Patients with no contraindications to chair lift testing (no O2 at the time of testing).
• Effective anticoagulation for at least 1 hour.

You may not qualify if:

• sPESI score = 0 with outpatient referral.
• Diagnostic confirmation of Pulmonia Embolism by thoracic angioscan or scintigraphy more than 24h after suspicion of diagnosis.
• Hospitalization \> 24h after introduction of anticoagulation, with subsequent confirmation by scintigraphy.
• Any sign of serious Pulmonia Embolism, requiring hospitalization in an intensive care unit.
• Asymptomatic Pulmonia Embolism discovered by chance

Sponsors & Collaborators

• University Hospital, Rouen: lead

Study Sites (1)

Chu Rouen

Rouen, 76031, France

RECRUITING

MeSH Terms

Conditions

Pulmonary Embolism; Ventricular Dysfunction, Right

Condition Hierarchy (Ancestors)

Lung Diseases; Respiratory Tract Diseases; Embolism; Embolism and Thrombosis; Vascular Diseases; Cardiovascular Diseases; Ventricular Dysfunction; Heart Diseases

Study Officials

• Delphine SIMON, MD

  University Hospital, Rouen

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Delphine SIMON, MD

CONTACT

2 32 88 73 97; delphine.simon@chu-rouen.fr

Armelle GUIDOTTI

CONTACT

232888265; armelle.guidotti@chu-rouen.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 4, 2023
• First Posted: December 12, 2023
• Study Start: February 9, 2024
• Primary Completion (Estimated): February 1, 2027
• Study Completion (Estimated): February 1, 2027
• Last Updated: February 17, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)